Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage San Diego oncology biotechnology company developing selective CDK2 and CDK4 inhibitors plus EGFR/HER3 and Nectin4/TROP2 bispecific antibody-drug conjugates for solid tumors, advancing four in-licensed programs toward approval and preparing to list on Nasdaq via a merger with Rallybio.
- Company typePrivate
- Founded2022
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Avenzo Therapeutics does
Avenzo Therapeutics is a clinical-stage oncology biotechnology company founded in San Diego in August 2022 by former Turning Point Therapeutics executives following Bristol Myers Squibb's $4.1 billion acquisition of Turning Point. The company is developing a portfolio of next-generation oncology therapeutics built on two proprietary technology pillars: highly selective small-molecule cyclin-dependent kinase (CDK) inhibitors — AVZO-021 (selective CDK2 inhibitor, in-licensed from Allorion Therapeutics) and AVZO-023 (selective CDK4 inhibitor, also from Allorion) — and bispecific antibody-drug conjugates (BsADCs) — AVZO-1418 (EGFR/HER3 BsADC from Duality Biotherapeutics' DIBAC platform) and AVZO-103 (Nectin4/TROP2 BsADC from VelaVigo). All four clinical-stage assets target solid tumor indications with high unmet need, principally HR+/HER2- breast cancer, NSCLC, and urothelial cancer; AVZO-021 and AVZO-023 are also being evaluated together with fulvestrant in the ORION-1 study to address CDK2-driven resistance to CDK4/6 therapy while sparing CDK6-associated hematologic toxicity. Three IND clearances were secured in 2025, two FDA Fast Track designations were granted in November 2025, and updated Phase 1/2 data for AVZO-021 were presented at the 2026 ASCO Annual Meeting.
The company operates a capital-intensive, equity-financed development model: total capital raised reached approximately $446 million through venture rounds (Series A and A-1 oversubscribed at $347M by March 2024, final $39M Series A top-up in November 2024, $60M Series B in September 2025), supplemented by a $215 million oversubscribed concurrent private placement announced in June 2026 in connection with a definitive all-stock merger with Rallybio Corporation under which the combined company will trade on Nasdaq as 'AVZO' (expected Q4 2026 close). Inbound licensing economics — $40M upfront to Allorion, $50M upfront to DualityBio, and option/option-exercise fees to VelaVigo — are the primary outflows alongside clinical-trial and CMC spend. Revenue is currently nil; future revenue is expected from commercialization of the four clinical-stage assets, potential symmetric out-licensing of assets to larger pharmaceutical partners, and licensing royalties, but no products are approved or priced today. Customers in the commercial sense do not yet exist; counterparties include licensors (Allorion, VelaVigo, DualityBio), a clinical supply partner (Gilead Sciences, providing Trodelvy for an AVZO-021 combination study), and ultimately, post-approval, oncology prescribers and payers.
Avenzo Therapeutics firmographics
Firmographics- Name
- Avenzo Therapeutics
- Legal name
- Avenzo Therapeutics, Inc.
- Website
- https://avenzotx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Avenzo Therapeutics is a clinical-stage San Diego oncology biotechnology company developing selective CDK2 and CDK4 inhibitors plus EGFR/HER3 and Nectin4/TROP2 bispecific antibody-drug conjugates for solid tumors, advancing four in-licensed programs toward approval and preparing to list on Nasdaq via a merger with Rallybio.
- Ownership category
- akta.pro rank
Avenzo Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
Keywords
Where Avenzo Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Avenzo Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Future product sales (post-approval): Pre-revenue clinical-stage biotechnology company with no marketed products. Future revenue expected from commercialization of clinical-stage assets (AVZO-021, AVZO-023, AVZO-1418, AVZO-103) subject to regulatory approval. Forward merger with Rallybio intended to provide Nasdaq listing to support future commercial launch.
- Licensing royalties (in-licensed asset economics): Inbound licensing model: Avenzo pays upfronts, development/regulatory/commercial milestones, and tiered royalties to licensors (Allorion, VelaVigo, DualityBio). Future symmetric out-licensing of assets to larger pharmaceutical partners expected to generate licensing royalties and milestone payments.
- Equity financing: Capital raised through successive private equity rounds: $196M initial financing (May 2023), $150M Series A-1 oversubscribed (Mar 2024), $386M total Series A/A-1 close (Nov 2024), $60M Series B (Sept 2025), and $215M concurrent oversubscribed private placement in connection with Rallybio merger (June 2026). Total capital raised approximately $446M as of September 2025.
Go-to-market motion1 record
Avenzo Therapeutics product offering
Product offeringCore offering
Avenzo Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation oncology therapeutics built on two proprietary technology pillars: (1) highly selective small-molecule cyclin-dependent kinase (CDK) inhibitors targeting CDK2 and CDK4 while sparing related CDKs to limit off-target toxicity, and (2) bispecific antibody-drug conjugates (BsADCs) engineered to co-target two tumor antigens and deliver cytotoxic payloads with enhanced tumor selectivity. The pipeline is anchored by AVZO-021 (CDK2i), AVZO-023 (CDK4i), AVZO-1418 (EGFR/HER3 BsADC), and AVZO-103 (Nectin4/TROP2 BsADC), combined with rational combination strategies including CDK4 + CDK2 inhibition with endocrine therapy for HR+/HER2- breast cancer.
Product overview
Avenzo Therapeutics is a clinical-stage biotechnology company developing next-generation oncology therapies as a portfolio of distinct drug candidates rather than a single product. Its pipeline comprises four clinical-stage assets: two small-molecule selective cyclin-dependent kinase inhibitors — AVZO-021 (lead CDK2 inhibitor, licensed from Allorion Therapeutics) and AVZO-023 (CDK4 inhibitor, also licensed from Allorion) — and two bispecific antibody-drug conjugates — AVZO-1418 (EGFR/HER3 BsADC, licensed from DualityBio) and AVZO-103 (Nectin4/TROP2 BsADC, licensed from VelaVigo). All programs are being advanced for solid tumor indications with high unmet need, primarily HR+/HER2- breast cancer and other tumors with elevated cyclin E expression, EGFR/HER3 co-expression, or Nectin4/TROP2 co-expression. The CDK2 and CDK4 inhibitors are also being explored together in the ORION-1 study for HR+/HER2- breast cancer, while each ADC is run under its own named first-in-human study (AVENTINE-1 for AVZO-1418; BEACON-1 for AVZO-103). The portfolio is supported by an additional preclinical program (AVZO-022) and by a clinical collaboration with Gilead Sciences evaluating AVZO-021 in combination with Trodelvy.
Differentiator
Problem solved
Functional benefit
Products and services
- AVZO-021 (ARTS-021) A potentially best-in-class, highly potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in-licensed from Allorion Therapeutics. Being studied in a Phase 1/2 clinical trial for HR+/HER2- metastatic breast cancer and other advanced solid tumors, including CCNE1-amplified cancers such as ovarian cancer. Also being evaluated in combination with Trodelvy (Gilead collaboration) and in combination with AVZO-023 in the ORION-1 study.
- AVZO-023 (ARTS-023) A potentially best-in-class, novel, highly potent and selective cyclin-dependent kinase 4 (CDK4) inhibitor in-licensed from Allorion Therapeutics for global (excluding Greater China) rights. Studied in the ORION-1 Phase 1/2 study as a single agent and in combination with AVZO-021 and/or endocrine therapy in HR+/HER2- breast cancer and other advanced solid tumors. Designed to spare CDK6-associated hematologic toxicity.
- AVZO-1418 (DB-1418) A potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC) in-licensed from Duality Biotherapeutics for global (excluding Greater China) rights. Built on DualityBio's proprietary Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform using a topoisomerase-1 inhibitor payload. Studied in the AVENTINE-1 Phase 1/2 study in advanced epithelial solid tumors including NSCLC, breast, and head and neck cancers.
- AVZO-103 (VAC-103) A potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (BsADC) in-licensed from VelaVigo for global (excluding Greater China) rights. Studied in the BEACON-1 Phase 1/2 study in locally advanced or metastatic urothelial cancer and other solid tumors. Designed to overcome resistance to standard-of-care therapies including enfortumab vedotin.
- AVZO-022 (ARTS-022) A potential best-in-class selective CDK4 inhibitor referenced in the Science section of the pipeline page; positioned for HR+ breast cancer and other advanced solid tumors. Listed as a preclinical program in the broader portfolio alongside AVZO-021/023.
Companies that use Avenzo Therapeutics
Customer profileIdeal customer profiles2 records
Avenzo Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Avenzo Therapeutics partnerships and signals
Strategic signalRecent moves7 records
Expansion highlights5 records
Avenzo Therapeutics competitors and assessment
Company assessmentDirect peers
- Olema Oncology: Clinical-stage oncology company developing targeted therapies for HR+/HER2- breast cancer, with lead asset palazestrant (OP-1250) being combined with CDK4/6 inhibitors. Highly comparable to Avenzo given overlapping breast cancer focus, CDK-combination strategy, and clinical-stage status.
- Mersana Therapeutics: Clinical-stage biotechnology company developing a portfolio of antibody-drug conjugates using proprietary platforms (Dolasynthen, Immunosynthen). Directly comparable to Avenzo as a clinical-stage ADC-focused developer with similar platform-driven pipeline strategy.
- Pyxis Oncology: Clinical-stage biotechnology company developing antibody-drug conjugates and bispecific antibodies for difficult-to-treat cancers. Directly comparable to Avenzo given the overlap in bispecific ADC pipeline strategy and clinical-stage profile.
- Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies including cell-cycle and DNA-damage response targets. Comparable to Avenzo as a clinical-stage oncology biotech with multiple programs in Phase 1/2 and similar pre-revenue profile.
- Arvinas: Clinical-stage biotechnology company developing PROTAC protein degraders, with lead estrogen-receptor degrader vepdegestrant in HR+/HER2- breast cancer (including CDK4/6 combinations). Highly comparable to Avenzo given the overlap in HR+/HER2- breast cancer clinical strategy and CDK-combination approach.
- Elevation Oncology: Clinical-stage oncology company developing targeted therapies for genomically defined solid tumors, with prior leadership overlap (Ryan Bloomer, Avenzo's SVP CMC, was previously SVP Technical Operations at Elevation). Comparable as a similarly sized clinical-stage oncology biotech with comparable stage and pre-revenue profile.
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric, mutation-targeted therapies. Comparable to Avenzo as a clinical-stage precision oncology biotech of similar stage, with multiple programs in early-stage clinical development.
Emerging players
- Bolt Biotherapeutics: Clinical-stage biotechnology company developing immune-stimulating antibody conjugates (ISACs), a next-generation ADC modality. Comparable to Avenzo's bispecific ADC pipeline as another clinical-stage developer of next-generation ADC platforms in oncology.
- Day One Biopharmaceuticals: Clinical and commercial-stage pediatric oncology company with board-level overlap (Avenzo independent director Garry Nicholson serves as Day One's Chairman). Comparable as a clinical-stage oncology company with a similar executive/board network and oncology drug development focus.
- Foghorn Therapeutics: Clinical-stage oncology company developing medicines targeting the chromatin regulatory system. Comparable to Avenzo as a clinical-stage oncology biotech with a platform-driven pipeline, similar pre-revenue profile, and broadly analogous scale and stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights8 records
Customer concentration
Avenzo Therapeutics social profiles
Digital presenceAvenzo Therapeutics compliance and trust
Trust signalCompliance3 records
Avenzo Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Avenzo Therapeutics leadership team
Management profileNumber of profiles
Profiles12 records
Avenzo Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries3 records
Avenzo Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Avenzo Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Avenzo Therapeutics
What does Avenzo Therapeutics do?
Avenzo Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation oncology therapeutics built on two proprietary technology pillars: (1) highly selective small-molecule cyclin-dependent kinase (CDK) inhibitors targeting CDK2 and CDK4 while sparing related CDKs to limit off-target toxicity, and (2) bispecific antibody-drug conjugates (BsADCs) engineered to co-target two tumor antigens and deliver cytotoxic payloads with enhanced tumor selectivity. The pipeline is anchored by AVZO-021 (CDK2i), AVZO-023 (CDK4i), AVZO-1418 (EGFR/HER3 BsADC), and AVZO-103 (Nectin4/TROP2 BsADC), combined with rational combination strategies including CDK4 + CDK2 inhibition with endocrine therapy for HR+/HER2- breast cancer.
Is Avenzo Therapeutics a public or private company?
Avenzo Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Avenzo Therapeutics founded?
Avenzo Therapeutics was founded in 2022. It employs 51 to 100 people.
Where is Avenzo Therapeutics based?
Avenzo Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Avenzo Therapeutics make money?
Three revenue lines are on record. Future product sales (post-approval) is the primary driver. The others are licensing royalties (in-licensed asset economics) and equity financing.
Who are Avenzo Therapeutics's main competitors?
Direct peers on record are Olema Oncology, Mersana Therapeutics, Pyxis Oncology, Repare Therapeutics, Arvinas, Elevation Oncology and Black Diamond Therapeutics. Emerging players are Bolt Biotherapeutics, Day One Biopharmaceuticals and Foghorn Therapeutics.
Does Avenzo Therapeutics have an API?
No public API is recorded for Avenzo Therapeutics.
What industry is Avenzo Therapeutics in?
Avenzo Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.